EMvision Medical Devices Ltd. (AU:EMV)
ASX:EMV
Want to see AU:EMV full AI Analyst Report?
EMV Stock Chart & Stats
AU$1.77
-AU$0.06(-3.19%)
At close: 4:00 PM EST
AU$1.77
-AU$0.06(-3.19%)
Day’s Range― - ―
52-Week RangeAU$1.48 - AU$2.43
Previous CloseN/A
Volume36.00K
Average Volume (3M)120.98K
Market Cap
AU$162.21M
Enterprise ValueAU$142.15M
Total Cash (Recent Filing)AU$17.56M
Total Debt (Recent Filing)AU$4.02M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding92,955,560
10 Day Avg. Volume127,185
30 Day Avg. Volume120,982
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)16.01
Price to Sales (P/S)29.42
P/FCF Ratio-18.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.15Price Target Upside77.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$5.50M
Bulls Say, Bears Say
Bulls Say
Addressable Market & Product FocusEMvision’s core product targets point-of-care brain imaging for stroke and TBI in emergency and pre-hospital settings. That focus aligns with a durable shift toward decentralized, rapid-diagnosis care and gives the company a clear, defensible clinical niche if it achieves regulatory and clinical validation.
Moderate LeverageA debt-to-equity around 0.38 indicates restrained financial leverage versus high-debt peers. This preserves flexibility to fund R&D or clinical programs without heavy interest burden, reducing bankruptcy risk and supporting execution over the next several months while commercialization progresses.
Strong Unit Economics (Gross Margin)A reported 100% gross profit margin suggests low incremental cost of goods or licensing-like economics at the unit level. If sustained and paired with revenue growth, these unit economics enable scalable profitability and margin improvement even while operating expenses are high during product commercialization.
Bears Say
Declining RevenuesRevenue falling more than 37% erodes the scale needed to dilute fixed R&D and regulatory costs. Without stable or growing sales, the company faces higher funding needs and reduced leverage with customers and regulators, increasing execution risk for commercial rollout over the medium term.
Negative Cash FlowsPersistent negative operating and free cash flows deplete reserves and force reliance on external financing. That constrains spending on clinical trials, manufacturing scale-up, and commercialization, heightening dilution risk and making sustained product development harder over the coming months.
Persistent Losses & Low ROENegative ROE and ongoing net losses show shareholder capital isn't producing returns. This reduces confidence from investors and limits access to non-dilutive capital, potentially forcing strategic trade-offs (cutting programs or diluting equity) that impair long-term value creation.
EMvision Medical Devices Ltd. News
EMV FAQ
What was EMvision Medical Devices Ltd.’s price range in the past 12 months?
EMvision Medical Devices Ltd. lowest share price was AU$1.48 and its highest was AU$2.43 in the past 12 months.
What is EMvision Medical Devices Ltd.’s market cap?
EMvision Medical Devices Ltd.’s market cap is AU$162.21M.
When is EMvision Medical Devices Ltd.’s upcoming earnings report date?
EMvision Medical Devices Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 106 days.
How were EMvision Medical Devices Ltd.’s earnings last quarter?
EMvision Medical Devices Ltd. released its earnings results on Feb 22, 2026. The company reported -AU$0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.044.
Is EMvision Medical Devices Ltd. overvalued?
According to Wall Street analysts EMvision Medical Devices Ltd.’s price is currently Undervalued.
Does EMvision Medical Devices Ltd. pay dividends?
EMvision Medical Devices Ltd. does not currently pay dividends.
What is EMvision Medical Devices Ltd.’s EPS estimate?
EMvision Medical Devices Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EMvision Medical Devices Ltd. have?
EMvision Medical Devices Ltd. has 92,955,560 shares outstanding.
What happened to EMvision Medical Devices Ltd.’s price movement after its last earnings report?
EMvision Medical Devices Ltd. reported an EPS of -AU$0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of EMvision Medical Devices Ltd.?
Currently, no hedge funds are holding shares in AU:EMV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EMvision Medical Devices Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.15 (77.97% Upside)
AU$3.15 (77.97% Upside)
Blogger Sentiment
Bullish
AU:EMV Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$18.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.44%
12-Months-Change
Fundamentals
Return on Equity
-70.29%
Trailing 12-Months
Asset Growth
25.56%
Trailing 12-Months
Company Description
EMvision Medical Devices Ltd.
EMvision Medical Devices Limited, a medical device company, engages in the research, development, and commercialization of imaging and diagnostic technology products. It develops a portable brain scanner for stroke diagnosis, monitoring, as well as other medical imaging needs. The company was incorporated in 2017 and is based in Macquarie Park, Australia.
EMV Stock 12 Month Forecast
Average Price Target
AU$3.15
▲(77.97% Upside)
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Cyclopharm Limited
―
Aroa Biosurgery Ltd
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---